Total Payments
$64,585
2021 Payments
$2,950
Companies
4
Transactions
50
Medicare Patients
2,534
Medicare Billing
$339,043
Payment Breakdown by Category
Consulting$64,585 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $64,585 | 50 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma Global Development | $31,940 | 5 | $0 (2018) |
| PFIZER INC. | $23,500 | 40 | $0 (2021) |
| MEDIVATION INC. | $8,800 | 4 | $0 (2017) |
| Janssen Research & Development, LLC | $345.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $2,950 | 8 | PFIZER INC. ($2,950) |
| 2020 | $3,050 | 8 | PFIZER INC. ($3,050) |
| 2019 | $5,100 | 8 | PFIZER INC. ($5,100) |
| 2018 | $41,290 | 17 | Astellas Pharma Global Development ($31,940) |
| 2017 | $12,195 | 9 | MEDIVATION INC. ($8,800) |
All Payment Transactions
50 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2021 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2021 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2021 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2021 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: ONCOLOGY | ||||||
| 08/18/2021 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2021 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: ONCOLOGY | ||||||
| 03/18/2021 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: ONCOLOGY | ||||||
| 01/28/2021 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2020 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2020 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $100.00 | General |
| Category: ONCOLOGY | ||||||
| 09/14/2020 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2020 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2020 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2020 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: ONCOLOGY | ||||||
| 03/26/2020 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: ONCOLOGY | ||||||
| 01/27/2020 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2019 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2019 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2019 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2019 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2019 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2019 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: ONCOLOGY | ||||||
| 03/21/2019 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2019 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $1,150.00 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2018 | PFIZER INC. | XTANDI (Drug) | Consulting Fee | Cash or cash equivalent | $100.00 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 414 | 420 | $181,717 | $32,943 |
| 2022 | 14 | 841 | 2,090 | $503,168 | $90,481 |
| 2021 | 12 | 690 | 714 | $531,825 | $105,698 |
| 2020 | 12 | 589 | 623 | $451,905 | $109,920 |
Total Patients
2,534
Total Services
3,847
Medicare Billing
$339,043
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2023 | 96 | 98 | $55,076 | $9,401 | 17.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 144 | 144 | $45,603 | $9,061 | 19.9% |
| 78812 | Nuclear medicine study from skull base to mid-thigh | Office | 2023 | 15 | 15 | $34,022 | $6,672 | 19.6% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Facility | 2023 | 61 | 64 | $11,046 | $2,062 | 18.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 19 | 20 | $11,240 | $1,922 | 17.1% |
| 78812 | Nuclear medicine study from skull base to mid-thigh | Facility | 2023 | 21 | 21 | $12,306 | $1,441 | 11.7% |
| 78830 | Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | Facility | 2023 | 16 | 16 | $4,500 | $856.35 | 19.0% |
| 78264 | Nuclear medicine study of stomach to assess emptying | Facility | 2023 | 20 | 20 | $3,083 | $587.09 | 19.0% |
| 78708 | Nuclear medicine study of kidney, blood, flow, and function with drug administration | Facility | 2023 | 11 | 11 | $2,563 | $519.97 | 20.3% |
| 78582 | Nuclear medicine study of lung ventilation and circulation | Facility | 2023 | 11 | 11 | $2,278 | $421.10 | 18.5% |
| 78812 | Nuclear medicine study from skull base to mid-thigh | Office | 2022 | 69 | 69 | $171,819 | $36,496 | 21.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2022 | 246 | 247 | $76,027 | $14,276 | 18.8% |
| 78812 | Nuclear medicine study from skull base to mid-thigh | Facility | 2022 | 191 | 194 | $113,684 | $13,560 | 11.9% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 28 | 28 | $33,426 | $10,361 | 31.0% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2022 | 54 | 54 | $30,348 | $5,295 | 17.4% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Facility | 2022 | 102 | 109 | $18,966 | $3,533 | 18.6% |
| 79101 | Radioactive drug therapy through a vein | Facility | 2022 | 19 | 23 | $9,129 | $1,792 | 19.6% |
| 78608 | Nuclear medicine study of brain with metabolic evaluation | Facility | 2022 | 17 | 17 | $23,732 | $899.66 | 3.8% |
| 78830 | Nuclear medicine study, 1 area with spect and concurrent ct scan | Facility | 2022 | 16 | 16 | $4,639 | $882.00 | 19.0% |
| 78813 | Nuclear medicine study whole body | Facility | 2022 | 14 | 14 | $5,334 | $876.61 | 16.4% |
| 78264 | Nuclear medicine study of stomach to assess emptying | Facility | 2022 | 26 | 26 | $4,104 | $791.14 | 19.3% |
| 78195 | Nuclear medicine study of lymphatic system | Facility | 2022 | 12 | 12 | $2,816 | $578.81 | 20.6% |
| 78708 | Nuclear medicine study of kidney, blood, flow, and function with drug administration | Facility | 2022 | 11 | 11 | $2,619 | $537.89 | 20.5% |
| 78580 | Nuclear medicine study of lung circulation | Facility | 2022 | 21 | 21 | $3,094 | $485.18 | 15.7% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2022 | 15 | 1,249 | $3,431 | $117.35 | 3.4% |
About Dr. Edwin Palmer, MD
Dr. Edwin Palmer, MD is a Nuclear Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1962492231.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edwin Palmer, MD has received a total of $64,585 in payments from pharmaceutical and medical device companies, with $2,950 received in 2021. These payments were reported across 50 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($64,585).
As a Medicare-enrolled provider, Palmer has provided services to 2,534 Medicare beneficiaries, totaling 3,847 services with total Medicare billing of $339,043. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Nuclear Medicine
- Other Specialties Nuclear Radiology, Diagnostic Radiology
- Location Boston, MA
- Active Since 10/26/2005
- Last Updated 08/09/2012
- Taxonomy Code 207U00000X
- Entity Type Individual
- NPI Number 1962492231
Products in Payments
- ENZALUTAMIDE (Drug) $31,940
- XTANDI (Drug) $27,150
- ZYTIGA (Drug) $345.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nuclear Medicine Doctors in Boston
Dr. James Thrall, Md, MD
Nuclear Medicine — Payments: $1.3M
Nuclear Medicine $1.3M
Barbara Mcneil, M.d., Ph.d, M.D., PH.D
Nuclear Medicine — Payments: $176,000
Nuclear Medicine $176,000
Dr. James Scott, Md, MD
Nuclear Medicine — Payments: $118,100
Nuclear Medicine $118,100
Heather Jacene, M.d, M.D
Nuclear Medicine — Payments: $8,948
Nuclear Medicine $8,948
Gustavo Mercier, Md Phd, MD PHD
Nuclear Medicine — Payments: $4,058
Nuclear Medicine $4,058
Dr. Shahein Tajmir, M.d, M.D
Nuclear Medicine — Payments: $2,464
Nuclear Medicine $2,464